Improvements in Sleep and Pruritus With Abrocitinib Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE DARE Study
Main Article Content
Keywords
Abrocitinib, atopic dermatitis, post hoc analysis
Abstract
Introduction Patients with atopic dermatitis (AD) may experience intense pruritus and sleep loss, constituting a substantial burden on quality of life. The objectives of this study were to assess the efficacy of abrocitinib versus dupilumab on sleep outcomes and pruritus in patients with moderate-to-severe AD.
Procedure/Study This post hoc analysis included data from adults (≥18 years) with moderate-to-severe AD who received oral abrocitinib (200 mg once daily) or subcutaneous dupilumab (300 mg once every 2 weeks following a 600-mg loading dose) with concomitant topical therapy in phase 3 JADE DARE (NCT04345367; 26 weeks). Assessments were least squares mean (LSM) change from baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) quantity of hours slept and sleep disturbance scores and SCORing Atopic Dermatitis (SCORAD) total score and visual analog scale (SCORAD-VAS) pruritus and sleep loss scores.
Results Data were included from 362 and 365 patients treated with abrocitinib and dupilumab, respectively. At Week 12, LSM change from baseline was greater with abrocitinib versus dupilumab for MOS-SS quantity of hours slept (0.7 [95% CI, 0.5, 0.9] vs 0.5 [0.2, 0.7]) and sleep disturbance (−20.5 [−22.3, −18.8] vs −16.4 [−18.1, −14.7]) scores. LSM change from baseline was greater for abrocitinib than dupilumab at Week 2 for SCORAD total score (−44.5 [95% CI, −47.0, −42.1] vs −33.5 [−35.9, −31.0]) and SCORAD-VAS sleep loss (−3.7 [−3.9, −3.4] vs −2.6 [−2.8, −2.3]) and pruritus (−4.2 [−4.4, −3.9] vs −2.8 [−3.0, −2.6]) scores. At Week 26, improvements across assessments were numerically greater with abrocitinib versus dupilumab.
Conclusion Patients experienced more rapid improvements in sleep and pruritus outcomes with abrocitinib 200 mg versus dupilumab, and improvements were consistently numerically greater with abrocitinib.
Funding/Disclosures This study was funded by Pfizer.
References
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.